he CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National Institute for Health and Care Excellence (NICE).
NICE released their final draft guidance today (31 January), recommending Casgevy coverage on the National Health Service (NHS). The therapy was co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
The institute said patients aged 12 and over with severe sickle cell disease, recurrent vaso-occlusive crises, and a certain genotype would qualify for treatment.
Casgevy is a one-time therapy that uses CRISPR/Cas9 gene-editing technology to modify a patient’s haematopoietic stem cells. The process targets the BBCL11A gene to increase foetal haemoglobin production, helping red blood cells function more effectively and reducing complications associated with sickle cell disease.
Unlike donor stem cell transplants – the only curative treatment currently available – Casgevy does not carry the same risk of rejection. However, it is only recommended for patients who are eligible for a transplant but lack a suitable donor.
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by approval for transfusion-dependent beta-thalassemia (TDT) in January 2024. NHS England reached an earlier reimbursement agreement for Casgevy in TDT in August 2024.
NICE previously declined to recommend Casgevy for NHS use in March 2024, citing insufficient evidence to justify its high cost. The therapy has a list price of £1.65m, and a commercial agreement was necessary to determine its affordability within the NHS. The confidential pricing agreement now allows Casgevy to be made available under a managed-access scheme, meaning further data will be collected as patients undergo treatment.
NHS England estimates that approximately 50 sickle cell disease patients per year will initially receive Casgevy, doubling the current number of patients who undergo stem cell transplants.
Patient representatives and advocacy groups have welcomed the agreement. Funmi Dasaglu, a sickle cell disease patient nominated by the Anthony Nolan charity to provide input to NICE, described the therapy as a transformative option. She highlighted the lack of effective treatments and the potential for Casgevy to improve patients’ quality of life.
Sickle Cell Society CEO John James stated that the approval was the result of extensive campaigning and represents a major breakthrough for patients.
NICE acknowledged that sickle cell disease disproportionately affects people from African, Caribbean, Middle Eastern, and South Asian backgrounds and stated that it considered these health inequalities when assessing Casgevy’s cost-effectiveness. The decision to approve the therapy was made with an understanding that additional evidence on long-term efficacy would be gathered over time.
Data collection through the managed-access agreement is expected to address uncertainties, particularly regarding the durability of the treatment’s benefits.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
